1
|
Ahangar P, Li J, Nkindi LS, Mohammadrezaee Z, Cooke ME, Martineau PA, Weber MH, Saade E, Nateghi N, Rosenzweig DH. A Nanoporous 3D-Printed Scaffold for Local Antibiotic Delivery. MICROMACHINES 2023; 15:83. [PMID: 38258202 PMCID: PMC10819679 DOI: 10.3390/mi15010083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 12/14/2023] [Accepted: 12/27/2023] [Indexed: 01/24/2024]
Abstract
Limitations of bone defect reconstruction include poor bone healing and osteointegration with acrylic cements, lack of strength with bone putty/paste, and poor osteointegration. Tissue engineering aims to bridge these gaps through the use of bioactive implants. However, there is often a risk of infection and biofilm formation associated with orthopedic implants, which may develop anti-microbial resistance. To promote bone repair while also locally delivering therapeutics, 3D-printed implants serve as a suitable alternative. Soft, nanoporous 3D-printed filaments made from a thermoplastic polyurethane and polyvinyl alcohol blend, LAY-FOMM and LAY-FELT, have shown promise for drug delivery and orthopedic applications. Here, we compare 3D printability and sustained antibiotic release kinetics from two types of commercial 3D-printed porous filaments suitable for bone tissue engineering applications. We found that both LAY-FOMM and LAY-FELT could be consistently printed into scaffolds for drug delivery. Further, the materials could sustainably release Tetracycline over 3 days, independent of material type and infill geometry. The drug-loaded materials did not show any cytotoxicity when cultured with primary human fibroblasts. We conclude that both LAY-FOMM and LAY-FELT 3D-printed scaffolds are suitable devices for local antibiotic delivery applications, and they may have potential applications to prophylactically reduce infections in orthopedic reconstruction surgery.
Collapse
Affiliation(s)
- Pouyan Ahangar
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada; (P.A.); (M.E.C.); (P.A.M.); (M.H.W.)
| | - Jialiang Li
- Department of Science, TAV College, Montreal, QC H3W 3E1, Canada; (J.L.); (L.S.N.); (Z.M.); (E.S.); (N.N.)
| | - Leslie S. Nkindi
- Department of Science, TAV College, Montreal, QC H3W 3E1, Canada; (J.L.); (L.S.N.); (Z.M.); (E.S.); (N.N.)
| | - Zohreh Mohammadrezaee
- Department of Science, TAV College, Montreal, QC H3W 3E1, Canada; (J.L.); (L.S.N.); (Z.M.); (E.S.); (N.N.)
| | - Megan E. Cooke
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada; (P.A.); (M.E.C.); (P.A.M.); (M.H.W.)
| | - Paul A. Martineau
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada; (P.A.); (M.E.C.); (P.A.M.); (M.H.W.)
| | - Michael H. Weber
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada; (P.A.); (M.E.C.); (P.A.M.); (M.H.W.)
| | - Elie Saade
- Department of Science, TAV College, Montreal, QC H3W 3E1, Canada; (J.L.); (L.S.N.); (Z.M.); (E.S.); (N.N.)
| | - Nima Nateghi
- Department of Science, TAV College, Montreal, QC H3W 3E1, Canada; (J.L.); (L.S.N.); (Z.M.); (E.S.); (N.N.)
| | - Derek H. Rosenzweig
- Department of Surgery, McGill University, Montreal, QC H3G 1A4, Canada; (P.A.); (M.E.C.); (P.A.M.); (M.H.W.)
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Centre, Montreal, QC H3G 1A4, Canada
| |
Collapse
|
2
|
Lorange JP, Ramirez Garcia Luna J, Grou-Boileau F, Rosenzweig D, Weber MH, Akoury E. Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis. J Bone Oncol 2023; 39:100470. [PMID: 36860585 PMCID: PMC9969300 DOI: 10.1016/j.jbo.2023.100470] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Revised: 01/19/2023] [Accepted: 02/05/2023] [Indexed: 02/11/2023] Open
Abstract
Background While considered the mainstay of treatment for specific bone metastases, ZA is used predominantly to treat osteolytic lesions. The purpose of this network meta-analysis is to compare ZA to other treatment options in its ability to improve specific clinical outcomes in patients with bone metastases secondary to any primary tumor. Methods PubMed, Embase and Web of Science were systematically searched from inception to May 5th, 2022. Keywords used were solid tumor, lung neoplasm, kidney neoplasm, breast neoplasm, prostate neoplasm, ZA and bone metastasis. Every randomized controlled trial and non-randomized quasi-experimental study of systemic ZA administration for patients with bone metastases and any comparator were included. A Bayesian network meta-analysis was done on the primary outcomes including number of SREs, time to developing a first on-study SRE, overall survival, and disease progression-free survival. Secondary outcome was pain at 3, 6 and 12 months after treatment. Results Our search yielded 3861 titles with 27 meeting inclusion criteria. For the number of SRE, ZA in combination with chemotherapy or hormone therapy was statistically superior to placebo (OR 0.079; 95 % CrI: 0.022-0.27). For the time to the first on study SRE, the relative effectiveness of ZA 4 mg was statistically superior to placebo (HR 0.58; 95 % CrI:0.48-0.77). At 3 and 6 months, ZA 4 mg was significantly superior to placebo for reducing pain with a SMD of -0.85 (95 % CrI:-1.6, -0.0025) and -2.6 (95 % CrI:-4.7, -0.52) respectively. Conclusions This systematic review shows the benefits of ZA in decreasing the incidence of SREs, increasing the time to the first on-study SRE, and reducing the pain level at 3 and 6 months.
Collapse
Affiliation(s)
| | - Jose Ramirez Garcia Luna
- Department of Surgery, Division of Orthopaedics, McGill University and The Research Institute of the McGill University Health Centre, Injury Repair Recovery Program, Montreal, Quebec, Canada
| | | | - Derek Rosenzweig
- Department of Surgery, Division of Orthopaedics, McGill University and The Research Institute of the McGill University Health Centre, Injury Repair Recovery Program, Montreal, Quebec, Canada
| | - Michael H. Weber
- Department of Surgery, Division of Orthopaedics, McGill University and The Research Institute of the McGill University Health Centre, Injury Repair Recovery Program, Montreal, Quebec, Canada
| | - Elie Akoury
- Department of Surgery, Division of Orthopaedics, McGill University and The Research Institute of the McGill University Health Centre, Injury Repair Recovery Program, Montreal, Quebec, Canada,Corresponding author.
| |
Collapse
|
3
|
Management of bone diseases: looking at scaffold-based strategies for drug delivery. Drug Deliv Transl Res 2023; 13:79-104. [PMID: 35816230 DOI: 10.1007/s13346-022-01191-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/24/2022] [Indexed: 12/13/2022]
Abstract
The bone tissue can regenerate itself completely and continuously; however, large-scale bone defects may overpower this self-regenerative process. Furthermore, the aging population, the increment in obesity incidence, and the sedentary lifestyles are serious risk factors for bone diseases' development which are associated with the self-regenerative process's failure, high morbidity, and mortality rates. Thus, there is an ever-growing need for strategic approaches targeting bone replacement, its remodelling, and its regeneration. Bone scaffolds have successfully been used as synthetic bone grafts for many years, yet recent bone tissue engineering strategies attempt to explore their multifunctionality by investigating them as drug delivery systems. Bone diseases' treatments can be substantially difficult due to the avascular nature of the surrounding cartilage; thus, targeted drug delivery to the bone can be advantageous: it provides local high drug concentrations and minimizes adverse effects while securing a space for new, healthy tissue growth. Despite the promising scientific progress, studies underlining bone scaffolds' use as local drug delivery systems are not abundant. Hence, this work reviews bone scaffolds' therapeutic interest for local drug delivery in five distinct bone disorders-osteomyelitis, osteoporosis, osteoarthritis, osteosarcoma, and cancer bone metastasis. Additionally, it presents the challenges of this possible therapeutic approach and its future perspectives. Albeit bone scaffolds present therapeutic benefits by acting as drug delivery systems, further pre-clinical and clinical assessments are needed to strengthen their understanding and enable research evidence translation into clinical practice. The mismatch between scientific evolution and regulatory frameworks remains one of the major future challenges.
Collapse
|
4
|
Mohseni Garakani M, Cooke ME, Weber MH, Wertheimer MR, Ajji A, Rosenzweig DH. A 3D, Compartmental Tumor-Stromal Microenvironment Model of Patient-Derived Bone Metastasis. Int J Mol Sci 2022; 24:ijms24010160. [PMID: 36613604 PMCID: PMC9820116 DOI: 10.3390/ijms24010160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/09/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
Bone is a frequent site of tumor metastasis. The bone-tumor microenvironment is heterogeneous and complex in nature. Such complexity is compounded by relations between metastatic and bone cells influencing their sensitivity/resistance to chemotherapeutics. Standard chemotherapeutics may not show efficacy for every patient, and new therapeutics are slow to emerge, owing to the limitations of existing 2D/3D models. We previously developed a 3D interface model for personalized therapeutic screening, consisting of an electrospun poly lactic acid mesh activated with plasma species and seeded with stromal cells. Tumor cells embedded in an alginate-gelatin hydrogel are overlaid to create a physiologic 3D interface. Here, we applied our 3D model as a migration assay tool to verify the migratory behavior of different patient-derived bone metastasized cells. We assessed the impact of two different chemotherapeutics, Doxorubicin and Cisplatin, on migration of patient cells and their immortalized cell line counterparts. We observed different migratory behaviors and cellular metabolic activities blocked with both Doxorubicin and Cisplatin treatment; however, higher efficiency or lower IC50 was observed with Doxorubicin. Gene expression analysis of MDA-MB231 that migrated through our 3D hybrid model verified epithelial-mesenchymal transition through increased expression of mesenchymal markers involved in the metastasis process. Our findings indicate that we can model tumor migration in vivo, in line with different cell characteristics and it may be a suitable drug screening tool for personalized medicine approaches in metastatic cancer treatment.
Collapse
Affiliation(s)
- Mansoureh Mohseni Garakani
- Chemical Engineering Department, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
- Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
| | - Megan E. Cooke
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC H3G 1A4, Canada
| | - Michael H. Weber
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC H3G 1A4, Canada
| | - Michael R. Wertheimer
- Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
- Department of Engineering Physics, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
| | - Abdellah Ajji
- Chemical Engineering Department, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
- Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC H3T1J4, Canada
- Correspondence: (A.A.); (D.H.R.); Tel.: +1-514-934-1934 (ext. 43238) (D.H.R.)
| | - Derek H. Rosenzweig
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC H3G 1A4, Canada
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC H3G 1A4, Canada
- Correspondence: (A.A.); (D.H.R.); Tel.: +1-514-934-1934 (ext. 43238) (D.H.R.)
| |
Collapse
|
5
|
Fairag R, Li L, Ramirez-GarciaLuna JL, Taylor MS, Gaerke B, Weber MH, Rosenzweig DH, Haglund L. A Composite Lactide-Mineral 3D-Printed Scaffold for Bone Repair and Regeneration. Front Cell Dev Biol 2021; 9:654518. [PMID: 34307346 PMCID: PMC8299729 DOI: 10.3389/fcell.2021.654518] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2021] [Accepted: 06/21/2021] [Indexed: 01/08/2023] Open
Abstract
Orthopedic tumor resection, trauma, or degenerative disease surgeries can result in large bone defects and often require bone grafting. However, standard autologous bone grafting has been associated with donor site morbidity and/or limited quantity. As an alternate, allografts with or without metallic or polyether-etherketone have been used as grafting substitutes. However, these may have drawbacks as well, including stress shielding, pseudarthrosis, disease-transmission, and infection. There is therefore a need for alternative bone substitutes, such as the use of mechanically compliant three-dimensional (3D)-printed scaffolds. Several off-the-shelf materials are available for low-cost fused deposition 3D printing such as polylactic acid (PLA) and polycaprolactone (PCL). We have previously described the feasibility of 3D-printed PLA scaffolds to support cell activity and extracellular matrix deposition. In this study, we investigate two medical-grade filaments consistent with specifications found in American Society for Testing and Materials (ASTM) standard for semi-crystalline polylactide polymers for surgical implants, a pure polymer (100M) and a copolymeric material (7415) for their cytocompatibility and suitability in bone tissue engineering. Moreover, we assessed the impact on osteo-inductive properties with the addition of beta-tricalcium phosphate (β-TCP) minerals and assessed their mechanical properties. 100M and 7415 scaffolds with the additive β-TCP demonstrated superior mesenchymal stem cells (MSCs) differentiation detected via increased alkaline phosphatase activity (6-fold and 1.5-fold, respectively) and mineralized matrix deposition (14-fold and 5-fold, respectively) in vitro. Furthermore, we evaluated in vivo compatibility, biosafety and bone repair potential in a rat femur window defect model. 100M+β -TCP implants displayed a positive biosafety profile and showed significantly enhanced new bone formation compared to 100M implants evidenced by μCT (39 versus 25% bone volume/tissue volume ratio) and histological analysis 6 weeks post-implantation. These scaffolds are encouraging composite biomaterials for repairing bone applications with a great potential for clinical translation. Further analyses are required with appropriate evaluation in a larger critical-sized defect animal model with long-term follow-up.
Collapse
Affiliation(s)
- Rayan Fairag
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC, Canada
- Research Institute of McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada
- Department of Orthopedic Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
| | - Li Li
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC, Canada
- Research Institute of McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada
| | | | | | | | - Michael H. Weber
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC, Canada
- Research Institute of McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada
| | - Derek H. Rosenzweig
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC, Canada
- Research Institute of McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada
| | - Lisbet Haglund
- Department of Surgery, Division of Orthopaedic Surgery, McGill University, Montreal, QC, Canada
- Research Institute of McGill University Health Center, Montreal General Hospital, Montreal, QC, Canada
- Shriners Hospital for Children, Montreal, QC, Canada
| |
Collapse
|
6
|
Cooke ME, Ramirez-GarciaLuna JL, Rangel-Berridi K, Park H, Nazhat SN, Weber MH, Henderson JE, Rosenzweig DH. 3D Printed Polyurethane Scaffolds for the Repair of Bone Defects. Front Bioeng Biotechnol 2020; 8:557215. [PMID: 33195122 PMCID: PMC7644785 DOI: 10.3389/fbioe.2020.557215] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 09/18/2020] [Indexed: 01/08/2023] Open
Abstract
Critical-size bone defects are those that will not heal without intervention and can arise secondary to trauma, infection, and surgical resection of tumors. Treatment options are currently limited to filling the defect with autologous bone, of which there is not always an abundant supply, or ceramic pastes that only allow for limited osteo-inductive and -conductive capacity. In this study we investigate the repair of bone defects using a 3D printed LayFomm scaffold. LayFomm is a polymer blend of polyvinyl alcohol (PVA) and polyurethane (PU). It can be printed using the most common method of 3D printing, fused deposition modeling, before being washed in water-based solutions to remove the PVA. This leaves a more compliant, micro-porous PU elastomer. In vitro analysis of dental pulp stem cells seeded onto macro-porous scaffolds showed their ability to adhere, proliferate and form mineralized matrix on the scaffold in the presence of osteogenic media. Subcutaneous implantation of LayFomm in a rat model showed the formation of a vascularized fibrous capsule, but without a chronic inflammatory response. Implantation into a mandibular defect showed significantly increased mineralized tissue production when compared to a currently approved bone putty. While their mechanical properties are insufficient for use in load-bearing defects, these findings are promising for the use of polyurethane scaffolds in craniofacial bone regeneration.
Collapse
Affiliation(s)
- Megan E. Cooke
- Biofabrication Laboratory, Research Institute of McGill University Health Centres, McGill University, Montreal, QC, Canada
- Department of Surgery, McGill University, Montreal, QC, Canada
| | - Jose L. Ramirez-GarciaLuna
- Department of Surgery, McGill University, Montreal, QC, Canada
- Bone Engineering Labs, Injury, Repair & Recovery Program, Research Institute McGill University Health Centres, McGill University, Montreal, QC, Canada
| | - Karla Rangel-Berridi
- Department of Surgery, McGill University, Montreal, QC, Canada
- Bone Engineering Labs, Injury, Repair & Recovery Program, Research Institute McGill University Health Centres, McGill University, Montreal, QC, Canada
| | - Hyeree Park
- Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada
| | - Showan N. Nazhat
- Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada
| | - Michael H. Weber
- Biofabrication Laboratory, Research Institute of McGill University Health Centres, McGill University, Montreal, QC, Canada
- Department of Surgery, McGill University, Montreal, QC, Canada
| | - Janet E. Henderson
- Department of Surgery, McGill University, Montreal, QC, Canada
- Bone Engineering Labs, Injury, Repair & Recovery Program, Research Institute McGill University Health Centres, McGill University, Montreal, QC, Canada
| | - Derek H. Rosenzweig
- Biofabrication Laboratory, Research Institute of McGill University Health Centres, McGill University, Montreal, QC, Canada
- Bone Engineering Labs, Injury, Repair & Recovery Program, Research Institute McGill University Health Centres, McGill University, Montreal, QC, Canada
| |
Collapse
|
7
|
Pitaru AA, Lacombe JG, Cooke ME, Beckman L, Steffen T, Weber MH, Martineau PA, Rosenzweig DH. Investigating Commercial Filaments for 3D Printing of Stiff and Elastic Constructs with Ligament-Like Mechanics. MICROMACHINES 2020; 11:mi11090846. [PMID: 32933035 PMCID: PMC7570386 DOI: 10.3390/mi11090846] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/09/2020] [Revised: 09/09/2020] [Accepted: 09/10/2020] [Indexed: 12/13/2022]
Abstract
The current gold standard technique for treatment of anterior cruciate ligament (ACL) injury is reconstruction with autograft. These treatments have a relatively high failure and re-tear rate. To overcome this, tissue engineering and additive manufacturing are being used to explore the potential of 3D scaffolds as autograft substitutes. However, mechanically optimal polymers for this have yet to be identified. Here, we use 3D printing technology and various materials with the aim of fabricating constructs better matching the mechanical properties of the native ACL. A fused deposition modeling (FDM) 3D printer was used to microfabricate dog bone-shaped specimens from six different polymers—PLA, PETG, Lay FOMM 60, NinjaFlex, NinjaFlex-SemiFlex, and FlexiFil—at three different raster angles. The tensile mechanical properties of these polymers were determined from stress–strain curves. Our results indicate that no single material came close enough to successfully match reported mechanical properties of the native ACL. However, PLA and PETG had similar ultimate tensile strengths. Lay FOMM 60 displayed a percentage strain at failure similar to reported values for native ACL. Furthermore, raster angle had a significant impact on some mechanical properties for all of the materials except for FlexiFil. We therefore conclude that while none of these materials alone is optimal for mimicking ACL mechanical properties, there may be potential for creating a 3D-printed composite constructs to match ACL mechanical properties. Further investigations involving co-printing of stiff and elastomeric materials must be explored.
Collapse
Affiliation(s)
- Audrey A. Pitaru
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
| | - Jean-Gabriel Lacombe
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
| | - Megan E. Cooke
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
| | - Lorne Beckman
- The Orthopaedics Research Lab, McGill University, Montreal, QC H3A 1A1, Canada; (L.B.); (T.S.)
| | - Thomas Steffen
- The Orthopaedics Research Lab, McGill University, Montreal, QC H3A 1A1, Canada; (L.B.); (T.S.)
| | - Michael H. Weber
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
| | - Paul A. Martineau
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
| | - Derek H. Rosenzweig
- Division of Orthopaedic Surgery, McGill University, Montreal, QC H3A 1A1, Canada; (A.A.P.); (J.-G.L.); (M.E.K.); (M.H.W.); (P.A.M.)
- Department of Experimental Surgery, McGill University, Montreal, QC H3A 1A1, Canada
- Injury, Repair and Recovery Program, Research Institute of McGill University Health Centre, Montreal, QC H3A 1A1, Canada
- Correspondence: ; Tel.: +01-514-934-1934 (ext. 43238)
| |
Collapse
|
8
|
Akoury E, Ramirez Garcia Luna AS, Ahangar P, Gao X, Zolotarov P, Weber MH, Rosenzweig DH. Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis. J Clin Med 2019; 8:E1212. [PMID: 31416169 PMCID: PMC6722631 DOI: 10.3390/jcm8081212] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Revised: 08/06/2019] [Accepted: 08/10/2019] [Indexed: 02/06/2023] Open
Abstract
Zoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects of lower doses Zol on lung cancer and lung cancer-induced bone metastasis cells over a longer time period. Human lung cancer (HCC827) and three bone metastases secondary to lung cancer (BML1, BML3 and BML4) cells were treated with Zol at 1, 3 and 10 µM for 7 days and then assessed for cell proliferation, migration, invasion and apoptosis. Low Zol treatment significantly decreased cell proliferation (1, 3 and 10 µM), migration (3 and 10 µM) and invasion (10 µM) while increasing apoptosis (10 µM) in lung cancer and metastatic cells. Our data exploits the potential of using low doses Zol for longer treatment periods and reinforces this approach as a new therapeutic regimen to impede the development of metastatic bone cancer while limiting severe side effects following high doses of systemic drug treatment.
Collapse
Affiliation(s)
- Elie Akoury
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada
| | - Ana Sofia Ramirez Garcia Luna
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada
- Medical Faculty Mannheim, Heidelberg University, D-68167 Mannheim, Germany
| | - Pouyan Ahangar
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada
| | - Xiaoya Gao
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada
| | - Pylyp Zolotarov
- Department of Pathology, McGill University Health Centre, Montreal, QC H4A 3J1, Canada
| | - Michael H Weber
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada
| | - Derek H Rosenzweig
- Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, Canada.
| |
Collapse
|
9
|
Current Biomedical Applications of 3D Printing and Additive Manufacturing. APPLIED SCIENCES-BASEL 2019. [DOI: 10.3390/app9081713] [Citation(s) in RCA: 75] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Additive manufacturing (AM) has emerged over the past four decades as a cost-effective, on-demand modality for fabrication of geometrically complex objects. The ability to design and print virtually any object shape using a diverse array of materials, such as metals, polymers, ceramics and bioinks, has allowed for the adoption of this technology for biomedical applications in both research and clinical settings. Current advancements in tissue engineering and regeneration, therapeutic delivery, medical device fabrication and operative management planning ensure that AM will continue to play an increasingly important role in the future of healthcare. In this review, we outline current biomedical applications of common AM techniques and materials.
Collapse
|